Ticker > Company >

Viyash Scientific share price

Viyash Scientific Ltd.

NSE: VIYASH BSE: 512529 SECTOR: Pharmaceuticals & Drugs  1.27 L   438   96

202.60
-4.75 (-2.29%)
BSE: 23 Jan 04:01 PM

Price Summary

Today's High

₹ 211

Today's Low

₹ 202

52 Week High

₹ 260.3

52 Week Low

₹ 111

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

5150.35 Cr.

Enterprise Value

5194.32 Cr.

No. of Shares

25.42 Cr.

P/E

381.76

P/B

4.36

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  46.49

CASH

0.41 Cr.

DEBT

44.38 Cr.

Promoter Holding

61.41 %

EPS (TTM)

₹  0.53

Sales Growth

5.78%

ROE

1.54 %

ROCE

2.24%

Profit Growth

2439.23 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year5.78%
3 Year-6.72%
5 Year-4.75%

Profit Growth

1 Year2439.23%
3 Year2.19%
5 Year-5.84%

ROE%

1 Year1.54%
3 Year0.33%
5 Year1.17%

ROCE %

1 Year2.24%
3 Year0.65%
5 Year1.61%

Debt/Equity

0.0424

Price to Cash Flow

-4578.09

Interest Cover Ratio

6.5677

CFO/PAT (5 Yr. Avg.)

0.373445360536613

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2025 61.41 0.00
Sep 2025 52.33 0.00
Jun 2025 52.61 0.00
Mar 2025 52.61 0.00
Dec 2024 52.61 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company’s PEG ratio is 0.156835879870451.
  • The company has an efficient Cash Conversion Cycle of 69.5458 days.
  • The company has a high promoter holding of 61.41%.

 Limitations

  • The company has shown a poor profit growth of 2.1927111791616% for the Past 3 years.
  • The company has shown a poor revenue growth of -6.7201334943615% for the Past 3 years.
  • Company has a poor ROE of 0.3297% over the past 3 years.
  • Company has a poor ROCE of 0.645433333333333% over the past 3 years
  • Company has negative cash flow from operations of -1.125.
  • The company has a low EBITDA margin of -5.98913817498192% over the past 5 years.
  • The company is trading at a high PE of 381.76.
  • The company is trading at a high EV/EBITDA of 149.5189.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 41.99 36.27 42.33 41.07 34.03
Total Expenditure 44.09 40.75 45.15 43.11 36.67
Operating Profit -2.1 -4.48 -2.82 -2.04 -2.64
Other Income 15.95 11.88 12.27 11.48 11.75
Interest 1 1.17 0.99 1.08 0.83
Depreciation 2.12 2.24 2.3 2.33 2.24
Exceptional Items -4.32 -0.31 -0.25 -1.25 -1.7
Profit Before Tax 6.41 3.68 5.91 4.78 4.34
Tax 2.15 0.87 1.68 1.41 1.26
Profit After Tax 4.26 2.81 4.23 3.37 3.08
Adjusted EPS (Rs) 0.17 0.11 0.17 0.13 0.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 265.46 219.63 222.69 168.52 178.26
Total Expenditure 241.5 231.59 249.09 195.18 189.64
Operating Profit 23.96 -11.97 -26.4 -26.66 -11.38
Other Income 31.3 38.86 28.29 45.98 50.94
Interest 2.68 1.61 2.51 4.36 3.96
Depreciation 9.13 9.59 9.12 8.94 8.67
Exceptional Items -2.56 0 0 -6.25 -4.88
Profit Before Tax 40.89 15.69 -9.75 -0.24 22.05
Tax 8.77 0.89 -3.67 -0.86 6.25
Net Profit 32.11 14.8 -6.08 0.62 15.79
Adjusted EPS (Rs.) 1.29 0.6 -0.24 0.02 0.63

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 49.67 49.67 49.89 49.89 50.06
Total Reserves 979.84 991.41 1008.48 1037.34 1092.59
Borrowings 0 0 0 0 0
Other N/C liabilities 4.81 19.26 -9.43 24.21 22.91
Current liabilities 96.62 89.56 61.61 98.16 75.56
Total Liabilities 1130.94 1149.9 1110.54 1209.59 1241.12
Assets
Net Block 65.78 66.9 56.72 42.52 46.18
Capital WIP 4.34 1.4 2.2 5.14 6.43
Intangible WIP 0 0 0 0 0.22
Investments 685.11 658.47 632.47 640.3 647.25
Loans & Advances 230.43 267.66 333.48 415.89 433.3
Other N/C Assets 0.29 0.6 10.65 8.97 0.22
Current Assets 144.99 154.86 75.02 96.78 107.53
Total Assets 1130.94 1149.9 1110.54 1209.59 1241.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 43.45 15.69 -9.75 -0.24 22.05
Adjustment 1.12 -6.38 -0.49 -18.19 -18.47
Changes in Assets & Liabilities -25.47 1.81 48.68 -10.77 -8.01
Tax Paid -16.76 -1.75 -0.7 2.26 3.31
Operating Cash Flow 2.34 9.36 37.75 -26.94 -1.13
Investing Cash Flow 16.55 -4.25 -50.7 5.47 -0.44
Financing Cash Flow -21.33 7.25 0.24 22.32 0.67
Net Cash Flow -2.44 12.36 -12.71 0.84 -0.9

Corporate Actions

Investors Details

PARTICULARS Dec 2024% Mar 2025% Jun 2025% Sep 2025% Dec 2025%
promoters 52.61 52.61 52.61 52.33 61.41
ca harbor investments 52.61 52.61 52.61 52.33 30.19
ca hull investments - - - - 31.22
PARTICULARS Dec 2024% Mar 2025% Jun 2025% Sep 2025% Dec 2025%
investors 47.39 47.39 47.39 47.67 38.59
haribabu bodepudi - - - - 2.77
investor education and pr... 0.01 0.01 - - 0.01
llp - - - - 0.89
quant mutual fund - quant... 9.04 - - 9.53 5.50
ashoka whiteoak icav - as... 1.63 1.48 1.48 1.47 -
investor education and pr... - - 0.02 0.02 -
quant mutual fund - quant... - 9.53 9.58 - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit FITCH
Credit FITCH
Credit INDIA RATINGS & RESEARCH
Credit INDIA RATINGS & RESEARCH
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research Nuvama
Research BP Wealth
Research BP Wealth
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q3FY25
Concall Q3FY24
Concall Q3FY23
Concall Q2FY26
Concall Q2FY25
Concall Q2FY21
Concall Q1FY25
Concall Q1FY23
Concall Q1FY21
Concall Q1FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY19
Presentation Q3FY24
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY21

Company News

Sequent Scientific informs about disclosure 17 Dec, 4:12 PM Sequent Scientific informs about updates 19 Nov, 3:26 PM Sequent Scientific informs about investor presentation 17 Nov, 5:03 PM Sequent Scientific informs about conference call 11 Nov, 1:44 PM Sequent Scientific informs about conference call 11 Aug, 3:35 PM Sequent Scientific - Quaterly Results 8 Aug, 12:49 PM Sequent Scientific - Quaterly Results 8 Aug, 12:49 PM Sequent Scientific - Quaterly Results 8 Aug, 12:49 PM Sequent Scientific informs about newspaper publication 16 Jul, 3:12 PM Sequent Scientific informs about reappointment of directors 14 Jul, 3:54 PM SeQuent secures approvals from NSE and BSE for proposed merger with Viyash Life Sciences 29 May, 12:59 PM Sequent Scientific informs about audio recording of earnings call and earnings presentation 21 May, 4:12 PM Sequent Scientific - Quaterly Results 20 May, 1:22 PM Sequent Scientific - Quaterly Results 20 May, 1:22 PM Sequent Scientific - Quaterly Results 20 May, 1:22 PM Sequent Scientific informs about voting results of postal ballot and scrutinizer’s report 20 Feb, 5:10 PM Sequent Scientific reports 39% fall in Q3 consolidated net profit 11 Feb, 5:00 PM Sequent Scientific - Quaterly Results 11 Feb, 1:13 PM Sequent Scientific - Quaterly Results 11 Feb, 1:13 PM Sequent Scientific - Quaterly Results 11 Feb, 1:13 PM Sequent Scientific - Quaterly Results 13 Nov, 8:30 PM Sequent Scientific - Quaterly Results 13 Nov, 8:30 PM Sequent Scientific informs about investor presentation 27 Sep, 9:55 AM Sequent Scientific receives WHO prequalification approval for Albendazole API 19 Aug, 5:58 PM Sequent Scientific - Quaterly Results 14 Aug, 7:49 PM Sequent Scientific informs about compliances-certificate 18 Jul, 5:00 PM Sequent Scientific informs about compliance report 30 May, 3:08 PM Sequent Scientific - Quaterly Results 15 May, 8:09 PM Sequent Scientific - Quaterly Results 15 May, 8:09 PM Sequent Scientific informs about analysts meet 13 May, 10:49 AM Sequent Scientific informs about resignation of Managing Director 4 Apr, 12:45 PM Sequent Scientific - Quaterly Results 13 Feb, 8:53 PM Sequent Scientific - Quaterly Results 13 Feb, 8:53 PM Sequent Scientific to sell plot located in Ambernath Industrial Area 8 Feb, 6:19 PM Sequent Scientific informs about transcript of earnings call 13 Nov, 5:17 PM Sequent Scientific - Quaterly Results 6 Nov, 10:02 PM Sequent Scientific - Quaterly Results 6 Nov, 10:02 PM USFDA completes inspection at Sequent Scientific’s Visakhapatnam manufacturing facility 25 Sep, 10:37 AM Sequent Scientific gets nod to sell API facility in Tarapur 15 Sep, 11:43 AM Sequent Scientific informs about rectification of inadvertent typographical error 17 Aug, 12:34 PM Sequent Scientific informs about audio recording of earnings call 11 Aug, 4:21 PM Sequent Scientific - Quaterly Results 10 Aug, 10:13 PM Sequent Scientific - Quaterly Results 10 Aug, 10:13 PM Sequent Scientific informs about appointment of director 8 Aug, 2:16 PM Sequent Scientific - Quaterly Results 23 May, 8:16 PM Sequent Scientific - Quaterly Results 23 May, 8:16 PM Sequent Scientific informs about conference call 17 May, 11:02 AM Sequent Scientific informs about non-applicability of large corporate entity 11 May, 5:23 PM Sequent Scientific informs about certificate 14 Apr, 3:46 PM Sequent Scientific informs about trading window closure 30 Mar, 1:06 PM

Viyash Scientific Stock Price Analysis and Quick Research Report. Is Viyash Scientific an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Viyash Scientific. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Viyash Scientific has a PE ratio of 390.352364801206 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Viyash Scientific has ROA of 1.2889% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Viyash Scientific has a Current ratio of 1.4231.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Viyash Scientific has a ROE of 1.5365%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Viyash Scientific has a Debt to Equity ratio of 0.0424 which means that the company has low proportion of debt in its capital.

  • Sales growth: Viyash Scientific has reported revenue growth of 5.7792% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Viyash Scientific for the current financial year is -6.3857239827889%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Viyash Scientific is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Viyash Scientific is Rs 0.5307. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Viyash Scientific in Ticker for free. Also, one can get the intrinsic value of Viyash Scientific by using Valuation Calculators, which are available with a Finology ONE subscription. 

Viyash Scientific FAQs

Q1. What is Viyash Scientific share price today?
Ans: The current share price of Viyash Scientific is Rs 207.16.

Q2. What is the market capitalisation of Viyash Scientific?
Ans: Viyash Scientific has a market capitalisation of Rs 5266.269236684 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Viyash Scientific?
Ans: The PE ratio of Viyash Scientific is 390.352364801206 and the P/B ratio of Viyash Scientific is 4.45643382036588, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Viyash Scientific share?
Ans: The 52-week high share price of Viyash Scientific is Rs 257.85, and the 52-week low share price of Viyash Scientific is Rs 117.35.

Q5. Does Viyash Scientific pay dividends?
Ans: Currently, Viyash Scientific does not pay dividends. Dividend yield of Viyash Scientific is around 0%.

Q6. What are the face value and book value of Viyash Scientific shares?
Ans: The face value of Viyash Scientific shares is Rs 2, while the book value per share of Viyash Scientific is around Rs 46.4856. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Viyash Scientific?
Ans: Viyash Scientific has a total debt of Rs 44.38 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Viyash Scientific?
Ans: The ROE of Viyash Scientific is 1.5365% and ROCE of Viyash Scientific is 2.2414%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Viyash Scientific a good buy for the long term?
Ans: The Viyash Scientific long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Viyash Scientific undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Viyash Scientific appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Viyash Scientific’s financials?
Ans: You can review Viyash Scientific’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Viyash Scientific
X